Please enable JavaScript.
Coggle requires JavaScript to display documents.
DNA Vaccines, Group 4 - Coggle Diagram
DNA Vaccines
when DNA vaccines enter the body
creating a strong cellular response
building a potent humoral, or antibody, response
prompt helper T cells and B cells
multiply and produce memory cells
activate cytotoxic “killer” T cells
gives long-lasting immunity
History
Purpose of curing HIV, cancer,....
the vast majority of vaccines are still in clinical trials
Began to test 1990
How to made?
Steps
isolate a gene from the
target pathogen.
splice it into a double-stranded DNA vector
replicate and
purify it in a laboratory
shot directly
into tissue through a “gene gun,”
from the virus or bacteria
Release to the public DNA vaccines
Vaccines are still in the testing phase
in clinical trials with human patients
mixed results
both cost-effective
well tolerated by patients
some concerns hamper their advancement
related to their ability
disrupt cellular processes
produce anti-DNA antibodies
too low a level of immunogenicity
this shows not effective enough
The technology for improving the vaccines’ efficacy
has advanced by leaps
since the 1990s
Predictions about dna vaccines
valued at nearly $244 million in 2013, expected to grow to $2.7 billion by 2019
DNA vaccines are not yet established in a vaccination schedule or routinely
will change in the relatively near future
new biotechnologies and nanotechnologies are helping to improve the vaccines
Effect
Defective
are related to their ability to disrupt cells
processing and production of anti-DNA antibodies
All are in clinical trials
Advantage
both cost effective
and is well tolerated by patients
The public is very much looking forward to it.
Group 4